Perspectives of Immune Suppression in the Tumor Microenvironment Promoting Oral Malignancy

Nobuo Kondoh1, *, Masako Mizuno-Kamiya2, Eiji Takayama1, Harumi Kawati1, Naoki Umemura1, Yutaka Yamazaki3, Kenji Mitsudo4, Iwai Tohnai4
1 Department of Oral Biochemistry, Division of Oral Structure, Function and Development, Asahi University School of Dentistry, 1851 Hozumi, Mizuho, Gifu, 501-0296, Japan
2 Department of Management and Information Studies, Chemistry Laboratory, Asahi University School of Business Administration, 1851 Hozumi, Mizuho, Gifu501-0296, Japan
3 Department of Oral Health Science, Gerodontology, Faculty of Dental Medicine and Graduate School of Dental Medicine, Hokkaido University, Kita-13, Nishi-7, Kita-ku, Sapporo, 060-8586, Japan
4 Department of Oral and Maxillofacial Surgery, Yokohama City University Graduate School of Medicine, 3-9 Fukuura, Kanazawa-ku, Yokohama, 236-0004, Japan

Article Metrics

CrossRef Citations:
Total Statistics:

Full-Text HTML Views: 367
Abstract HTML Views: 323
PDF Downloads: 270
ePub Downloads: 232
Total Views/Downloads: 1192
Unique Statistics:

Full-Text HTML Views: 218
Abstract HTML Views: 152
PDF Downloads: 125
ePub Downloads: 90
Total Views/Downloads: 585

© 2018 Kondoh et al.

open-access license: This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International Public License (CC-BY 4.0), a copy of which is available at: ( This license permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

* Address correspondence to this author at the Department of Oral Biochemistry, Asahi University School of Dentistry, 1851 Hozumi, Mizuho, Gifu, 501-0296, Japan; Tel: +81-058-329-1416; E-mail:



In order to survive, cancers control immune systems and evade immune detection using mediators consisting of immune checkpoint molecules and cellular systems associated with immune suppression.


During the development of cancer and chronic infections, the immune checkpoints and cellular components including regulatory T cells, myeloid derived suppressor cells and cancer associated fibroblasts are often enhanced as a mechanism of immune subversion and have therefore become very important therapeutic targets.


In this review, we will discuss the complexity of immune-suppressive mechanisms in the tumor milieu of cancers, including oral malignancy.

Keywords: Immune suppression, Tumor Microenvironment (TME), T-Regulatory cell (Treg), Myeloid Derived Suppressor Cell (MDSC), Cancer-Associated Fibroblasts (CAFs), Oral malignancy.


Accumulated evidence suggests that the progression and malignancy of tumors, including Oral Squamous Cell Carcinoma (OSCC), is not only promoted by the aggressive phenotypes of tumor cells, but is also regulated by the biological influences of the micro environments within the tumor tissue that affect the host’s immunological response [1]. Overexpression of immunosuppressive cytokines, such as IL-10, TGF-β and IL-1β can cultivate a Tumor Microenvironment (TME) conducive to evasion and tumor proliferation [2-4]. Cross talk between cancer and stromal cells including Cancer Associated Fibroblast (CAF) is mediated by IL-1β, and several other cytokine cascades [5]. The role of the immune suppressive mechanisms that are utilized by Myeloid-Derived Suppressor Cells (MDSCs) is essential for the suppression of T cell activity [6]. Co-evolution of both epithelial and stromal phenotypes contributes to carcinogenesis [7]. There are specific metabolic pathways that have been identified and shown to contribute to the enhancement of regulatory T (Treg) cells to suppress anti-tumor immunity [8]. The complex activity within immune checkpoint molecules include both inhibitory and co-stimulatory pathways that are located between Antigen Presenting Cells (APC) and effector T cells (or effector Treg), which can counteract T-cell mediated immunity due to exhaustion of the T cells by activated Treg and MDSCs [9]. The aim of this review is to summarize the immune suppressive networks that could therefore provide novel strategies to overcome T cell exhaustion [10], and to provide a clue for effective immunotherapeutics against OSCCs and other cancers [11].


The regulation of T cell activity requires at least two signals mediated by receptors. First, it requires T cell receptors which specifically engage peptides presented by Major Histocompatibility Complexes (MHCs) on Antigen-Presenting Cells (APCs). Second, T cell activation requires CD28 as a receptor for B7 family ligands that are located on APCs [12]. The aberrant expression of T cell co-stimulatory (B7 family) molecules in the tumor milieu has been attributed to the suppression of anti-tumor immunity. Cytotoxic T-Lymphocyte-Associated Protein-4 (CTLA-4; also known as CD152) is one of the first inhibitory receptors shown to be a suppressor of T cell response [13]. CTLA-4 is structurally similar to CD28 and binds to CD80 (B7-1) / CD86 (B7-2) on APCs (or tumor cells) at a higher affinity than CD28, which suggests an interference with T cell activation [14]. Overexpression of CTLA-4 is associated with a poor prognosis or higher clinical stages in nasopharyngeal carcinoma and breast cancer, respectively [15, 16]. CTLA-4 is the first immune check point targeted in the treatment of cancer. The blocking of CTLA-4 reduces tumor growth in murine models, including melanoma, and colon carcinoma [17, 18]. Both CD86 and CTLA-4 showed significant overexpression in the OSCC tissues with differentially methylated promoters [19]. Association of CTLA-4 gene polymorphism with OSCC has also been reported [20].

Another immunological checkpoint that facilitates tumor cell evasion involves the interaction between Programmed Death-1 (PD-1; CD279) and Programmed Death Receptor Ligand-1 (PD-L1; also known as CD274 or B7-H1). PD-1 is first identified as a type-I transmembrane receptor in a murine T-cell hybridoma clone undergoing Activation-Induced Cell Death (AICD) [21]. A recent study evidenced that CTLA-4 and PD-1 exert their effects at different stages of T-cell activation. CTLA-4 works mainly at the T cell priming stage in the lymph nodes, whereas PD-1 mainly promotes the cells in the periphery [22]. The expression of PD-1 on T cells has become one of the hallmarks of exhausted T cells. In multiple human tumors, a significant proportion of Tumor Infiltrating Lymphocytes (TILs) express PD-1 and are often associated with impaired CD8+ T cell function [23, 24]. In OSCCs, a correlation was shown between PD-L1 and tumor size and lymph node metastasis or other malignant phenotypes [25, 26]. Interestingly, however, the expression of PD-1 and PD-L1 in blood and lesion samples is elevated in both patients with OSCCs and pre-malignant actinic cheilitis [27]. These results suggest that the evasion of T cell activity by PD-L1 through signals of PD-1 is essential for the progression of OSCCs.

PD-1/PD-L1 interaction has been implicated in promoting the induction of Treg cells [28]; the blocking of PD-1 by antibodies suppresses TGF-β and retinoic acid-induced Treg conversion from naïve T cells, and treatment with a PD-1-blocking antibody in combination with a tumor vaccine was shown to reduce Treg infiltration into tumors in vivo [29]. Different immune checkpoint inhibitors including PD-1 and CTLA-4 can work synergistically due to non-redundant mechanisms. The synergistic blocking of PD-1 and CTLA-4 enhances and prolongs the efficacy of cancer vaccine to reject B16 melanoma cells by elevating the CD8+ / Treg ratio [30]. Studies have confirmed the drastic synergy effects of vaccines against tumor neoantigens with immune check point inhibitors. These studies have demonstrated that anti-CTLA4 treatments provide a highly effective immune therapy for melanoma [31, 32] and anti PD-1 treatments are highly advantageous for non-small cell lung cancers [33]. Positive results have also been observed for oral malignancies, whereby a combination of platinum-based chemotherapy and treatment with nivolumab, PD-1 monoclonal antibody resulted in a longer overall survival rate for patients with recurrent squamous-cell carcinoma of the head and neck [34].

Another potentially significant protein is the Inducible Co-Stimulator Ligand (ICOSL), also known as B7-H2. It shares homology with CD28, and similar to CTLA-4, it is induced following T cell activation [35]. In melanoma patients, the specific expansion of ICOS positive Tregs following high-dose IL-2 therapy correlates with worse clinical prognoses [36]. Acute myeloid leukemia patients exhibiting ICOSL positivity had significantly decreased survival [37]. The polymorphisms of the CTLA-4 in combination with ICOS seems to be possible predisposing factors for OSCC [38]. Interestingly, ICOS/ICOSL axis could have a dual effect to participate in anti-tumor T cell response as well as a pro-tumor response connecting with Tregs’ activity, therefore both antagonist and agonist antibodies targeting this pathway could be effective for cancer treatment. [39].

B7-H3 is part of the B7 family whose receptor remains unidentified. The in vivo expression of B7-H3 is reported in OSCC [40]. Contradictory findings show both co-stimulatory and co-inhibitory functions [41-44]. B7-H4 also represents a T cell-co-inhibitory molecule whose expression in the tumor milieu has been associated with poor prognosis of esophageal carcinoma [45], OSCC [46] and ovarian carcinoma [47, 48]. Tumor-Associated Macrophages (TAMs) express high levels of B7-H4, which is attributed to the presence of IL-6 and IL-10 [48]. Although, ligands on T cells are unidentified, the mobilization of stromal cells for immune evasion involving B7-H3 and B7-H4 could be similarly regulated by OSCCs.

V domain-containing Ig Suppressor of T-cell Activation (VISTA) is a member of the B7 family that bears homology to PD-L1 and is exclusively expressed within the hematopoietic compartment. VISTA overexpression on tumor cells interferes with protective antitumor immunity in vivo in mice [49] and human OSCCs [50].


CD4+CD25+cells, Tregs, are identified as a naturally occurring CD4+ T-cell subset (about 5-10% of all peripheral T cells) by Sakaguchi and colleagues [51]. Most Tregs are generated in the thymus, and serve as regulators of overloaded immune reaction. It has been suggested that the Forkhead Box P3 (FoxP3) transcription factor represents an intracellular marker for Treg. There are also other markers, including CTLA-4, Glucocorticoid-Induced TNF Receptor (GITR), Lymphocyte Activation Gene-3 (LAG-3), and neuropilin [51]. FoxP3 transcription factor represses IL-2 production of Tregs, which also expresses IL-2 receptor (CD25). Therefore, for the survival of Tregs, an outer supply of IL-2 is essential [52]. In tumor tissues, many Tregs develop into effector Tregs which express CTLA-4, PD-1 or CCR6 at higher levels, and engage in the disruption of host immune systems including those in OSCC patients [53-55]. The elevated Foxp3 protein expression is a predictive factor for OSCC progression [56]. A higher frequency of double-labelled FoxP3+ and Toll-Like Receptor Protein 2 (TLR2)+ Tregs is observed within the immune cells of OSCC patients [57]. So, the blockade of Treg function using particular TLR ligands may be a potential target for therapeutic strategy.


MDSCs are a heterogenic cell population consisting of immature myeloid progenitors and precursors of granulocyte, macrophages and dendritic cells [58]. They are expanded in chronic, environmental, or tumor-associated inflammations and exert immune-suppressive effects, as well as supporting tumor growth and metastasis in a number of ways [59-62].

MDSCs have been described in tumor-bearing mice, in which they can be identified by the cell surface markers of CD11b and Gr-1 [63, 64]. They are further subdivided into two populations using Gr-1 isoforms Ly6G and Ly6C. The differential expression of these molecules distinguishes monocytic (M)-MDSCs from granulocytic (PMN)-MDSCs. M-MDSCs are CD11b+Ly6C+ Ly6Glow/-; PMN-MDSCs are CD11b+Ly6C-Ly6G+ [65, 66]. Since humans lack an analogue of Gr-1, the human M-MDSCs are CD11b+CD14+CD15-IL4Ra+HLA-DRlowCD33+; PMN-MDSCs are CD11b+CD14-CD15+HLA-DRlow/-CD33+ [67].

Whereas MDSCs exist at a very low level in healthy peripheral blood, in cancer patients the population is expanded [6, 68]. The expansion of MDSCs is induced by pro-inflammatory cytokines including VEGF, IL-1β, IL-6, IL-17 and TNF-α. VEGF inhibits Dendritic Cell (DC) development via NF-kB activity while driving MDSC accumulation [69]. IL-1β is a potent inducer of MDSC accumulation and suppressive activity [70] and IL-6 is a downstream mediator of the IL-1β-induced expansion of MDSC [71]. While IL-17 is an inducer of MDSC, the effects may be mediated by IL-6 [72]. Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) is required for DC differentiation; however, high levels of GM-CSF induce MDSC accumulation [73]. TNF-α induces M-MDSC to promote immune tolerance [74]. Prostaglandin (PG) E2 is an inflammatory chemical mediator generated by Cyclooxygenase (COX)2. Many tumors, as well as tumor-infiltrating cells, produce PGE2. PGE2 promotes MDSC differentiation, while elimination of COX2 or PGE2 in tumor bearing mice reduces MDSC differentiation [75]. High Mobility Group Box (HMGB)1 is released from myeloid cells as a response to sepsis, infection, or arthritis. HMGB1 promotes the development of MDSCs from bone marrow progenitor cells, and resulted in the increased production of IL-10 [76]. Tumor-derived lactate is a product of the “Warburg effect” [77]. The lactate also develops MDSCs, and blunts immune surveillance [78, 79].

M-MDSCs are highly immunosuppressive and exert their regulatory activity mostly in an antigen-nonspecific manner. In contrast, PMN-MDSCs are moderately immunosuppressive and suppress immune responses mainly by antigen-specific mechanisms [80]. Both subsets of MDSCs are expanded systemically in a number of human malignancies. Renal cell carcinoma, colorectal cancer, and hepatocellular carcinoma are associated with PMN-MDSC, while glioblastoma, ovarian cancer and multiple myeloma are associated with M-MDSC. Metastatic melanoma and non-small cell lung cancer are associated with both types of MDSCs [81]. Expression of VISTA and MDSC markers are also correlated with the poor prognosis in primary OSCC [50].

In order to compare the immune-modulatory effects of OSCCs in primary and advanced stages, we have established a metastasized model (L5-11cells) representing more malignant phenotypes than the parental OSCC (Sq-1979 cells) when implanted in the syngeneic mice [82]. Our results revealed that it is metastasized L5-11 cells, not early-stage Sq-1979 cells that predominantly induce PMN-MDSCs in tumor-bearing mice [83]; this is not simply reflecting the differential tumor size, since even the larger amount of inoculation of Sq1979 cells could not induce the MDSC cells in the mice. We have also confirmed that the quantity of IFN-γ produced by stimulated spleen cells is significantly suppressed in mice implanted with Sq-1979 and L5-11 cells; however, the production of IL-10 is significantly elevated in mice implanted with Sq-1979 while markedly suppressed in L5-11 cell-implanted mice [84]. Thus, our results demonstrated that unlike primary OSCC cells, the metastasized OSCC cells have acquired immunomodulatory functions mediated by PMN-MDSCs.

MDCSs utilize multiple suppressive mechanisms to promote tumor expansion. They directly suppress T cells by starving them of amino acids, inducing apoptosis, and reducing their intracellular signaling. MDSC-inducing immune suppressions are mediated by Arginase (ARG)1, inducible NOS (iNOS), NO [85-87], sequestration of cysteine, and decreased expression of E-selectin [88, 89]. In the case of OSCC patients, CD14+/CD16+ monocyte-derived macrophages, a potential subpopulation of MDSCs, are increased in circulating peripheral blood [90]. The effect of MDSCs on the systemic immunity of advanced-stage OSCC patients may be the cause of the increased proportion of CD57+ T cells [91], or the higher levels of Th2 in combination with relatively lower levels of Th1 cytokines [92].


Several lines of evidence have demonstrated that stromal cells surrounding tumor cells play important roles in developing tumor tissues. High-grade invasive OSCC cells specifically induce PD-L1 on dendritic cells in the TME [93]. In head and neck cancers, CAFs have been suggested to promote angiogenesis, invasion metastases, and Treg induction via several cytokines including HGF, IL-33, IL-6, CCL2, CCL7, TGF-β1, VEGF and TNF-α [2]. CAF-educated macrophage progenitor cells reduce T cell proliferation via TGF-β1, IL-10 and ARG1, suggesting that CAFs can induce protumoral TAMs in the tumor immunosuppressive microenvironment [94]. In OSCC tissues, CAFs are divided into 3 grades on the basis of the expression of alpha smooth muscle actin, and the CAFs in the higher grade promote CD163 positive macrophage which is associated with poor prognosis [95]. Constitutive production of IL-1β from OSCCs enhances IL-6 production of CAFs [4]. IL-6 and GM-CSF, produced by pancreatic CAFs, are important mediators of MDSC differentiation [96]. Our results using a mouse OSCC model suggest that the immune-suppressive function of mesenchymal stromal cells is specifically enhanced by humoral factor(s) from primary OSCC cells [97], which, however, do not induce any MDSCs in the tumor-bearing mice [84]. Therefore, immune-modulatory functions of OSCC that are dependent on mesenchymal stromal cells and MDSCs can be uniquely regulated according to their malignant stages.


The immune system plays an important role in the development and progression of OSCCs and other cancers. As already mentioned, recent cancer immunotherapies have targeted the molecules in the tumor microenvironment of immune check point inhibitors including CTLA4 [17, 18, 29-32], PD-1 [29, 33, 34] or ICOS [39].

The histopathology of oral malignancies has shown that some OSCCs develop from Oral Potentially Malignant Disorders (OPMDs) in a complex tissue microenvironment. Such examples of OPMDs include: Oral Erythroplakia (OE), oral leukoplakia (OLK), oral lichenplanus (OLP) [98, 99]. Of these, it is, OLP that is most remarkable histologically due to its high number of lymphocytes. There are various therapeutic attempts being performed that aim to re-organize the microenvironment components of OLP. These treatments commonly include Thalidomide, an immune stimulant that inhibits TNF-α and stimulates T cells, M1 macrophage and NK cells [100, 101]. Another immune-stimulant, curucumin [102] has also proven effective in OLP treatments.

The use of steroids is another mainstay treatment for OLP because of their potential to inhibit immune cells that reduce cytokine production [103]. Other therapies recruited in the treatment of OLP employ the use of mycophenolate, a potent suppressor of B and T cells and chemokines [104], and pimecrolimus, which is a calcineurin inhibitor that has a suppressive effect on cytokines [105].


As summarized in Fig. (1), there are several mediators involving specific cytokines and cellular systems associated with tumor evasion of host immune systems. Our results demonstrate that the immunosuppressive efficacy of OSCC milieu is developed in a stepwise manner depending on the stages of OSCCs [84]. In the early stage, mesenchymal stromal cells (i.e., CAF) could be a unique effector; humoral factor(s) from OSCC cells force CAF to exert immune suppression via the direct cell contacts to effector T cells [97]. Potentiated CAF could also affect other immune-suppressive mediators such as Treg, TAM and MDSCs. In the advanced stage, MDSCs could possibly be a major conductor of immune-suppression [83]. In the TME, the effector Treg, harboring CCR6, PD-1 and CTLA-4, could be mobilized by antigens and/or chemokines secreted from OSCC cells. As shown in Fig. (1), there are several cytokines, immune-check points, and cellular components among the TME of OSCC. However, how OSCCs differentially utilize the immune modulatory aspects involving CAFs, MDSCs and several other factors is not fully understood. Further elucidation of the regulatory pathways structured by tumor-host interactions could identify important therapeutic targets in OSCC development.

Fig. (1). A schematic illustration of the cellular components and factors responsible for the immune-suppressive mechanisms in the tumor micro environment. Cellular components including Oral Square Cell Carcinoma (OSCC), Myeloid Derived Suppressor Cell (MDSC), Cancer Associated Fibroblast (CAF), Tumor Associated Macrophage (TAM), regulatory T cells (Tregs) and effector T cells, interact mutually using soluble factors, including Interleukins (ILs), C-C Chemokine Ligands (CCLs), Tumor Necrosis Factor (TNF)-α, Tumor Growth Factor (TGF)-β, High Mobility Group Box (HMGB) 1, Granulocyte Macrophage-Colony Stimulating Factor (GM-CSF), Vascular Endothelial Growth Factor (VEGF), Arginase (Arg) 1, Prostaglandin (PG) E2, Nitric Oxide (NO) and lactate. CAFs and Tregs can also interact directly with effector T cells via receptor-ligand interactions, including Programmed cell Death (PD)-1, Cytotoxic T-Lymphocyte-Associated Protein (CTLA)-4, Inducible Co-Stimulator Ligand (ICOSL), V Domain-Containing Ig Suppressor of T-Cell Activation (VISTA) and C-C Chemokine Receptor (CCR) 6.


Not applicable.


The authors declare no conflict of interest, financial or otherwise.


The authors would like to express their deepest thanks to Ms. Masako Sawada for her excellent secretarial assistance. This work was financially supported in part by the Grants-in-Aid for Scientific Research from the Japan Society for the Promotion of Science KAKENHI Grant Number (17K11891).


[1] Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144(5): 646-74.
[2] Takahashi H, Sakakura K, Kawabata-Iwakawa R, et al. Immunosuppressive activity of cancer-associated fibroblasts in head and neck squamous cell carcinoma. Cancer Immunol Immunother 2015; 64(11): 1407-17.
[3] Arantes DA, Costa NL, Mendonça EF, Silva TA, Batista AC. Overexpression of immunosuppressive cytokines is associated with poorer clinical stage of oral squamous cell carcinoma. Arch Oral Biol 2016; 61: 28-35.
[4] Dudás J, Fullár A, Bitsche M, et al. Tumor-produced, active interleukin-1β regulates gene expression in carcinoma-associated fibroblasts. Exp Cell Res 2011; 317(15): 2222-9.
[5] Bae JY, Kim EK, Yang DH, et al. Reciprocal interaction between carcinoma-associated fibroblasts and squamous carcinoma cells through interleukin-1α induces cancer progression. Neoplasia 2014; 16(11): 928-38.
[6] Parker KH, Beury DW, Ostrand-Rosenberg S. Myeloid-Derived Suppressor Cells: Critical cells driving immune suppression in the tumor microenvironment. Adv Cancer Res 2015; 128: 95-139.
[7] Franco OE, Shaw AK, Strand DW, Hayward SW. Cancer associated fibroblasts in cancer pathogenesis. Semin Cell Dev Biol 2010; 21(1): 33-9.
[8] De Rosa V, Di Rella F, Di Giacomo A, Matarese G. Regulatory T cells as suppressors of anti-tumor immunity: Role of metabolism. Cytokine Growth Factor Rev 2017; 35: 15-25.
[9] Dyck L, Mills KHG. Immune checkpoints and their inhibition in cancer and infectious diseases. Eur J Immunol 2017; 47(5): 765-79.
[10] Pauken KE, Wherry EJ. Overcoming T cell exhaustion in infection and cancer. Trends Immunol 2015; 36(4): 265-76.
[11] Butt AQ, Mills KH. Immunosuppressive networks and checkpoints controlling antitumor immunity and their blockade in the development of cancer immunotherapeutics and vaccines. Oncogene 2014; 33(38): 4623-31.
[12] Ceeraz S, Nowak EC, Noelle RJ. B7 family checkpoint regulators in immune regulation and disease. Trends Immunol 2013; 34(11): 556-63.
[13] Linsley PS, Brady W, Urnes M, Grosmaire LS, Damle NK, Ledbetter JA. CTLA-4 is a second receptor for the B cell activation antigen B7. J Exp Med 1991; 174(3): 561-9.
[14] van der Merwe PA, Bodian DL, Daenke S, Linsley P, Davis SJ. CD80 (B7-1) binds both CD28 and CTLA-4 with a low affinity and very fast kinetics. J Exp Med 1997; 185(3): 393-403.
[15] Huang PY, Guo SS, Zhang Y, et al. Tumor CTLA-4 overexpression predicts poor survival in patients with nasopharyngeal carcinoma. Oncotarget 2016; 7(11): 13060-8.
[16] Mao H, Zhang L, Yang Y, et al. New insights of CTLA-4 into its biological function in breast cancer. Curr Cancer Drug Targets 2010; 10(7): 728-36.
[17] Duraiswamy J, Kaluza KM, Freeman GJ, Coukos G. Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors. Cancer Res 2013; 73(12): 3591-603.
[18] Hodi FS, Corless CL, Giobbie-Hurder A, et al. Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin. J Clin Oncol 2013; 31(26): 3182-90.
[19] Basu B, Chakraborty J, Chandra A, et al. Genome-wide DNA methylation profile identified a unique set of differentially methylated immune genes in oral squamous cell carcinoma patients in India. Clin Epigenetics 2017; 9: 13.
[20] Wong YK, Chang KW, Cheng CY, Liu CJ. Association of CTLA-4 gene polymorphism with oral squamous cell carcinoma. J Oral Pathol Med 2006; 35(1): 51-4.
[21] Ishida Y, Agata Y, Shibahara K, Honjo T. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J 1992; 11(11): 3887-95.
[22] Buchbinder EI, Desai A. CTLA-4 and PD-1 pathways: Similarities, differences, and implications of their inhibition. Am J Clin Oncol 2016; 39(1): 98-106.
[23] Ahmadzadeh M, Johnson LA, Heemskerk B, et al. Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood 2009; 114(8): 1537-44.
[24] Matsuzaki J, Gnjatic S, Mhawech-Fauceglia P, et al. Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer. Proc Natl Acad Sci USA 2010; 107(17): 7875-80.
[25] Oliveira-Costa JP, de Carvalho AF, da Silveira GG, et al. Gene expression patterns through oral squamous cell carcinoma development: PD-L1 expression in primary tumor and circulating tumor cells. Oncotarget 2015; 6(25): 20902-20.
[26] Hirai M, Kitahara H, Kobayashi Y, et al. Regulation of PD-L1 expression in a high-grade invasive human oral squamous cell carcinoma microenvironment. Int J Oncol 2017; 50(1): 41-8.
[27] Malaspina TS, Gasparoto TH, Costa MR, et al. Enhanced programmed death 1 (PD-1) and PD-1 ligand (PD-L1) expression in patients with actinic cheilitis and oral squamous cell carcinoma. Cancer Immunol Immunother 2011; 60(7): 965-74.
[28] Francisco LM, Salinas VH, Brown KE, et al. PD-L1 regulates the development, maintenance, and function of induced regulatory T cells. J Exp Med 2009; 206(13): 3015-29.
[29] Dyck L, Wilk MM, Raverdeau M, Misiak A, Boon L, Mills KH. Anti-PD-1 inhibits Foxp3+ Treg cell conversion and unleashes intratumoural effector T cells thereby enhancing the efficacy of a cancer vaccine in a mouse model. Cancer Immunol Immunother 2016; 65(12): 1491-8.
[30] Curran MA, Montalvo W, Yagita H, Allison JP. PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc Natl Acad Sci USA 2010; 107(9): 4275-80.
[31] van Rooij N, van Buuren MM, Philips D, et al. Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma. J Clin Oncol 2013; 31(32): e439-42.
[32] Snyder A, Makarov V, Merghoub T, et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med 2014; 371(23): 2189-99.
[33] Rizvi NA, Hellmann MD, Snyder A, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 2015; 348(6230): 124-8.
[34] Ferris RL, Blumenschein G Jr, Fayette J, et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med 2016; 375(19): 1856-67.
[35] Sharpe AH, Freeman GJ. The B7-CD28 superfamily. Nat Rev Immunol 2002; 2(2): 116-26.
[36] Sim GC, Martin-Orozco N, Jin L, et al. IL-2 therapy promotes suppressive ICOS+ Treg expansion in melanoma patients. J Clin Invest 2014; 124(1): 99-110.
[37] Tamura H, Dan K, Tamada K, et al. Expression of functional B7-H2 and B7.2 costimulatory molecules and their prognostic implications in de novo acute myeloid leukemia. Clin Cancer Res 2005; 11(16): 5708-17.
[38] Kämmerer PW, Toyoshima T, Schöder F, et al. Association of T-cell regulatory gene polymorphisms with oral squamous cell carcinoma. Oral Oncol 2010; 46(7): 543-8.
[39] Amatore F, Gorvel L, Olive D. Inducible Co-Stimulator (ICOS) as a potential therapeutic target for anti-cancer therapy. Expert Opin Ther Targets 2018; 22(4): 343-51.
[40] Zhang SS, Tang J, Yu SY, et al. Expression levels of B7-H3 and TLT-2 in human oral squamous cell carcinoma. Oncol Lett 2015; 10(2): 1063-8.
[41] Chapoval AI, Ni J, Lau JS, et al. B7-H3: a costimulatory molecule for T cell activation and IFN-gamma production. Nat Immunol 2001; 2(3): 269-74.
[42] Suh WK, Gajewska BU, Okada H, et al. The B7 family member B7-H3 preferentially down-regulates T helper type 1-mediated immune responses. Nat Immunol 2003; 4(9): 899-906.
[43] Wang L, Fraser CC, Kikly K, et al. B7-H3 promotes acute and chronic allograft rejection. Eur J Immunol 2005; 35(2): 428-38.
[44] Prasad DV, Nguyen T, Li Z, et al. Murine B7-H3 is a negative regulator of T cells. J Immunol 2004; 173(4): 2500-6.
[45] Wang L, Cao NN, Wang S, Man HW, Li PF, Shan BE. Roles of coinhibitory molecules B7-H3 and B7-H4 in esophageal squamous cell carcinoma. Tumour Biol 2016; 37(3): 2961-71.
[46] Wu L, Deng WW, Yu GT, et al. B7-H4 expression indicates poor prognosis of oral squamous cell carcinoma. Cancer Immunol Immunother 2016; 65(9): 1035-45.
[47] Fauci JM, Straughn JM Jr, Ferrone S, Buchsbaum DJ. A review of B7-H3 and B7-H4 immune molecules and their role in ovarian cancer. Gynecol Oncol 2012; 127(2): 420-5.
[48] Kryczek I, Zou L, Rodriguez P, et al. B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma. J Exp Med 2006; 203(4): 871-81.
[49] Wang L, Rubinstein R, Lines JL, et al. VISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responses. J Exp Med. 2011, 14; 208(3): 577-92.
[50] Wu L, Deng WW, Huang CF, et al. Expression of VISTA correlated with immunosuppression and synergized with CD8 to predict survival in human oral squamous cell carcinoma. Cancer Immunol Immunother 2017; 66(5): 627-36.
[51] Sakaguchi S. Naturally arising CD4+ regulatory T cells for immunologic self-tolerance and negative control of immune responses. Annu Rev Immunol 2004; 22: 531-62.
[52] Setoguchi R, Hori S, Takahashi T, Sakaguchi S. Homeostatic maintenance of natural Foxp3(+) CD25(+) CD4(+) regulatory T cells by interleukin (IL)-2 and induction of autoimmune disease by IL-2 neutralization. J Exp Med 2005; 201(5): 723-35.
[53] Miyara M, Sakaguchi S. Natural regulatory T cells: mechanisms of suppression. Trends Mol Med 2007; 13(3): 108-16.
[54] Sakaguchi S, Wing K, Onishi Y, Prieto-Martin P, Yamaguchi T. Regulatory T cells: how do they suppress immune responses? Int Immunol 2009; 21(10): 1105-11.
[55] Lee JJ, Kao KC, Chiu YL, et al. Enrichment of Human CCR6+ Regulatory T Cells with Superior Suppressive Activity in Oral Cancer. J Immunol 2017; 199(2): 467-76.
[56] Song JJ, Zhao SJ, Fang J, et al. Foxp3 overexpression in tumor cells predicts poor survival in oral squamous cell carcinoma. BMC Cancer 2016; 16: 530.
[57] Hussaini HM, Parachuru VPB, Seymour GJ, Rich AM. Forkhead box-P3+ regulatory T cells and toll-like receptor 2 co-expression in oral squamous cell carcinoma. Acta Histochem 2017; 119(3): 205-10.
[58] Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system.Nat Rev Immunol 2000; 9(3): 162-74.
[59] Condamine T, Ramachandran I, Youn JI, Gabrilovich DI. Regulation of tumor metastasis by myeloid-derived suppressor cells. Annu Rev Med 2015; 66: 97-110.
[60] Marvel D, Gabrilovich DI. Myeloid-derived suppressor cells in the tumor microenvironment: expect the unexpected. J Clin Invest 2015; 125(9): 3356-64.
[61] Damuzzo V, Pinton L, Desantis G, et al. Complexity and challenges in defining myeloid-derived suppressor cells. Cytometry B Clin Cytom 2015; 88(2): 77-91.
[62] Boros P, Ochando J, Zeher M. Myeloid derived suppressor cells and autoimmunity. Hum Immunol 2016; 77(8): 631-6.
[63] Gabrilovich DI, Ostrand-Rosenberg S, Bronte V. Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol 2012; 12(4): 253-68.
[64] Talmadge JE, Gabrilovich DI. History of myeloid-derived suppressor cells. Nat Rev Cancer 2013; 13(10): 739-52.
[65] Yazdani Y, Mohammadnia-Afrouzi M, Yousefi M, et al. Myeloid-derived suppressor cells in B cell malignancies. Tumour Biol 2015; 36(10): 7339-53.
[66] Motallebnezhad M, Jadidi-Niaragh F, Qamsari ES, Bagheri S, Gharibi T, Yousefi M. The immunobiology of myeloid-derived suppressor cells in cancer. Tumour Biol 2016; 37(2): 1387-406.
[67] Montero AJ, Diaz-Montero CM, Kyriakopoulos CE, Bronte V, Mandruzzato S. Myeloid-derived suppressor cells in cancer patients: A clinical perspective. J Immunother 2012; 35(2): 107-15.
[68] Almand B, Clark JI, Nikitina E, et al. Increased production of immature myeloid cells in cancer patients: A mechanism of immunosuppression in cancer. J Immunol 2001; 166(1): 678-89.
[69] Oyama T, Ran S, Ishida T, et al. Vascular endothelial growth factor affects dendritic cell maturation through the inhibition of nuclear factor-kappa B activation in hemopoietic progenitor cells. J Immunol 1998; 160(3): 1224-32.
[70] Ostrand-Rosenberg S, Sinha P. Myeloid-derived suppressor cells: linking inflammation and cancer. J Immunol 2009; 182(8): 4499-506.
[71] Bunt SK, Yang L, Sinha P, Clements VK, Leips J, Ostrand-Rosenberg S. Reduced inflammation in the tumor microenvironment delays the accumulation of myeloid-derived suppressor cells and limits tumor progression. Cancer Res 2007; 67(20): 10019-26.
[72] Wang L, Yi T, Zhang W, Pardoll DM, Yu H. IL-17 enhances tumor development in carcinogen-induced skin cancer. Cancer Res 2010; 70(24): 10112-20.
[73] Morales JK, Kmieciak M, Knutson KL, Bear HD, Manjili MH. GM-CSF is one of the main breast tumor-derived soluble factors involved in the differentiation of CD11b-Gr1- bone marrow progenitor cells into myeloid-derived suppressor cells. Breast Cancer Res Treat 2010; 123(1): 39-49.
[74] Yang F, Li Y, Wu T, et al. TNFα-induced M-MDSCs promote transplant immune tolerance via nitric oxide. J Mol Med (Berl) 2016; 94(8): 911-20.
[75] Eruslanov E, Daurkin I, Ortiz J, Vieweg J, Kusmartsev S. Pivotal Advance: Tumor-mediated induction of myeloid-derived suppressor cells and M2-polarized macrophages by altering intracellular PGE2 catabolism in myeloid cells. J Leukoc Biol 2010; 88(5): 839-48.
[76] Parker KH, Sinha P, Horn LA, et al. HMGB1 enhances immune suppression by facilitating the differentiation and suppressive activity of myeloid-derived suppressor cells. Cancer Res 2014; 74(20): 5723-33.
[77] Pedersen PL. The cancer cell’s “power plants” as promising therapeutic targets: An overview. J Bioenerg Biomembr 2007; 39(1): 1-12.
[78] Husain Z, Huang Y, Seth P, Sukhatme VP. Tumor-derived lactate modifies antitumor immune response: effect on myeloid-derived suppressor cells and NK cells. J Immunol 2013; 191(3): 1486-95.
[79] Brand A, Singer K, Koehl GE, et al. LDHA-associated lactic acid production blunts tumor immunosurveillance by T and NK cells. Cell Metab 2016; 24(5): 657-71.
[80] Wynn TA. Myeloid-cell differentiation redefined in cancer. Nat Immunol 2013; 14(3): 197-9.
[81] Stromnes IM, Greenberg PD, Hingorani SR. Molecular pathways: myeloid complicity in cancer. Clin Cancer Res 2014; 20(20): 5157-70.
[82] Adachi M, Mizuno-Kamiya M, Takayama E, et al. Gene expression analyses associated with malignant phenotypes of metastatic sub-clones derived from a mouse oral squamous cell carcinoma Sq-1979 cell line. Oncol Lett 2018; 15(3): 3350-6. [DOI: 10.3892/ol.2017.7648].
[83] Sumi S, Umemura N, Takayama E, et al. Metastasized murine oral squamous cell carcinoma cells induce intratumoral polymorphonuclear myeloid derived suppressor cells. Oncol Rep 2017; 37(5): 2897-904.
[84] Azuma Y, Mizuno-Kamiya M, Takayama E, et al. The producing capabilities of interferon-γ and interleukin-10 in primary and metastasized oral squamous cell carcinoma cells. Cancer Transl Med 2017; 3(6): 194-9. [DOI: 10.4103/ctm.ctm_30_17].
[85] Peláez B, Campillo JA, López-Asenjo JA, Subiza JL. Cyclophosphamide induces the development of early myeloid cells suppressing tumor cell growth by a nitric oxide-dependent mechanism. J Immunol 2001; 166(11): 6608-15.
[86] Wu AA, Drake V, Huang HS, Chiu S, Zheng L. Reprogramming the tumor microenvironment: Tumor-induced immunosuppressive factors paralyze T cells. OncoImmunology 2015; 4(7): e1016700.
[87] Baritaki S, Huerta-Yepez S, Sahakyan A, et al. Mechanisms of nitric oxide-mediated inhibition of EMT in cancer: Inhibition of the metastasis-inducer Snail and induction of the metastasis-suppressor RKIP. Cell Cycle 2010; 9(24): 4931-40.
[88] Srivastava MK, Sinha P, Clements VK, Rodriguez P, Ostrand-Rosenberg S. Myeloid-derived suppressor cells inhibit T-cell activation by depleting cystine and cysteine. Cancer Res 2010; 70(1): 68-77.
[89] Hanson EM, Clements VK, Sinha P, Ilkovitch D, Ostrand-Rosenberg S. Myeloid-derived suppressor cells down-regulate L-selectin expression on CD4+ and CD8+ T cells. J Immunol 2009; 183(2): 937-44.
[90] Grimm M, Feyen O, Coy JF, Hofmann H, Teriete P, Reinert S. Analysis of circulating CD14+/CD16+ monocyte-derived macrophages (MDMs) in the peripheral blood of patients with oral squamous cell carcinoma. Oral Surg Oral Med Oral Pathol Oral Radiol 2016; 121(3): 301-6.
[91] Iida M, Takayama E, Naganawa K, et al. Increase of peripheral blood CD57+ T-cells in patients with oral squamous cell carcinoma. Anticancer Res 2014; 34(10): 5729-34.
[92] Gaur P, Singh AK, Shukla NK, Das SN. Inter-relation of Th1, Th2, Th17 and Treg cytokines in oral cancer patients and their clinical significance. Hum Immunol 2014; 75(4): 330-7.
[93] Hirai M, Kitahara H, Kobayashi Y, et al. Regulation of PD-L1 expression in a high-grade invasive human oral squamous cell carcinoma microenvironment. Int J Oncol 2017; 50(1): 41-8.
[94] Takahashi H, Sakakura K, Kudo T, et al. Cancer-associated fibroblasts promote an immunosuppressive microenvironment through the induction and accumulation of protumoral macrophages. Oncotarget 2017; 8(5): 8633-47.
[95] Fujii N, Shomori K, Shiomi T, et al. Cancer-associated fibroblasts and CD163-positive macrophages in oral squamous cell carcinoma: their clinicopathological and prognostic significance. J Oral Pathol Med 2012; 41(6): 444-51.
[96] Mace TA, Ameen Z, Collins A, et al. Pancreatic cancer-associated stellate cells promote differentiation of myeloid-derived suppressor cells in a STAT3-dependent manner. Cancer Res 2013; 73(10): 3007-18.
[97] Inagaki T, Mizunno-Kamiya M, Takayama E, et al. Suppressive effect of mesenchymal stromal cells on interf eron-γ-producing capability of spleen cells was specifically enhanced via humoral mediator(s) from mouse oral squamous cell carcinoma Sq-1979 cells in vitro. Cancer Transl Med 2018; 4(1): 9-16. [DOI: 10.4103/ctm.ctm_34_17].
[98] Warnakulasuriya S, Johnson NW, van der Waal I. Nomenclature and classification of potentially malignant disorders of the oral mucosa. J Oral Pathol Med 2007; 36(10): 575-80.
[99] Walsh T, Liu JL, Brocklehurst P, et al. Clinical assessment to screen for the detection of oral cavity cancer and potentially malignant disorders in apparently healthy adults. Cochrane Database Syst Rev 2013; 21(11): CD010173.
[100] Jin X, Lu S, Xing X, et al. Thalidomide: features and potential significance in oral precancerous conditions and oral cancer. J Oral Pathol Med 2013; 42(5): 355-62.
[101] Wu Y, Zhou G, Zeng H, Xiong CR, Lin M, Zhou HM. A randomized double-blind, positive-control trial of topical thalidomide in erosive oral lichen planus. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2010; 110(2): 188-95.
[102] Kia SJ, Shirazian S, Mansourian A, Khodadadi Fard L, Ashnagar S. Comparative efficacy of topical curcumin and triamcinolone for oral lichen planus: A randomized, controlled clinical trial. J Dent (Tehran) 2015; 12(11): 789-96.
[103] Thongprasom K, Dhanuthai K. Steriods in the treatment of lichen planus: A review. J Oral Sci 2008; 50(4): 377-85.
[104] Wee JS, Shirlaw PJ, Challacombe SJ, Setterfield JF. Efficacy of mycophenolate mofetil in severe mucocutaneous lichen planus: A retrospective review of 10 patients. Br J Dermatol 2012; 167(1): 36-43.
[105] McCaughey C, Machan M, Bennett R, Zone JJ, Hull CM. Pimecrolimus 1% cream for oral erosive lichen planus: A 6-week randomized, double-blind, vehicle-controlled study with a 6-week open-label extension to assess efficacy and safety. J Eur Acad Dermatol Venereol 2011; 25(9): 1061-7.